Synthesis and biological evaluation of N-(4-hydroxy-3-mercaptonaphthalen-1- yl)amides as inhibitors of angiogenesis and tumor growth

European Journal of Medicinal Chemistry

Volumn 64, Issue , 2013, Pages 377-388

  Xu, Fuming ^a   Jia, Yuping ^b   Wen, Qingli ^c   Wang, Xuejian ^a   Zhang, Lei ^a   Zhang, Yingjie ^a   Yang, Kanghui ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Institute of Pharmaceutical Industry   (China)

^c WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; HUVECs; Inhibitor; Kinase; Rat thoracic aorta rings; Tube formation

Indexed keywords

4 CHLORO N (4 HYDROXY 3 ((1 METHYL 1H TETRAZOL 5 YL) THIO)NAPHTHALEN 1 YL)BENZAMIDE; 4 CHLORO N (4 HYDROXY 3 ((5 METHYL 1,3,4 THIADIAZOL 2 YL) THIO)NAPHTHALEN 1 YL)BENZAMIDE; AMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZENE; EPIDERMAL GROWTH FACTOR RECEPTOR; N (3 ((1,3,4 THIADIAZOL 2 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 4 CHLOROBENZAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 2 NAPHTHAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 2 NITROBENZAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 3 (3,4 DIMETHOXYPHENYL)ACRYLAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 3 (4 CHLOROPHENYL)ACRYLAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 3 (4 NITROPHENYL)ACRYLAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 3 METHOXYBENZAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 3 METHYLBENZAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 3 NITROBENZAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 4 CHLOROBENZAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 4 METHOXYBENZAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 4 NITROBENZAMIDE; N (3 ((1H 1,2,4 TRIAZOL 5 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL)CINNAMAMIDE; N (3 ((7H PURIN 6 YL)THIO) 4 HYDROXYNAPHTHALEN 1 YL) 4 CHLOROBENZAMIDE; N (4 HYDROXY 3 MERCAPTONAPHTHALEN 1 YL)AMIDE; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; STAUROSPORINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HCT116; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; THORACIC AORTA; UMBILICAL VEIN ENDOTHELIAL CELL;

AMIDES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; AORTA, THORACIC; CELL LINE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; K562 CELLS; MALE; MCF-7 CELLS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84877056672     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.03.043     Document Type: Article

References (43)

1. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364 (Pubitemid 26272076)
2. J. Folkman Tumor angiogenesis Advances in Cancer Research 43 1985 175 203
3. R.S. Kerbel Tumor angiogenesis: past, present and future Carcinogenesis 21 2000 505 515 (Pubitemid 30137936)
4. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70 (Pubitemid 30046295)
5. N. Ferrara Vascular endothelial growth factor as a target for anticancer therapy The Oncologist 9 2004 2 10 (Pubitemid 38747842)
6. A.F. Karamysheva Mechanisms of angiogenesis Biochemistry (Moscow) 73 2008 751 762
7. R. Bose, and X. Zhang The ErbB kinase domain: structural perspectives into kinase activation and inhibition Experimental Cell Research 315 2009 649 658
8. K. Pietras, T. Sjöblom, K. Rubin, C.-H. Heldin, and A. Östman PDGF receptors as cancer drug targets Cancer Cell 3 2003 439 443 (Pubitemid 38340290)
9. P.S. Sharma, R. Sharma, and T. Tyagi Receptor tryosine kinase inhibitors as potent weapons in war against cancers Current Pharmaceutical Design 15 2009 758 776
10. A. Östman, and C.H. Heldin PDGF receptors as targets in tumor treatment Advances in Cancer Research 97 2007 247 274 (Pubitemid 46528991)
11. G. G The rationale and future potential of angiogenesis inhibitors in neoplasia Drugs 58 1999 17 38
12. R.S. Kerbel Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312 2006 1171 1175 (Pubitemid 43801134)
13. S. Mahboobi, A. Sellmer, A. Eswayah, S. Elz, A. Uecker, and F.-D. Böhmer Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides - a SAR study on the bioisosterism of pyrimidine and imidazole European Journal of Medicinal Chemistry 43 2008 1444 1453 (Pubitemid 351885215)
14. S.J. Kaspersen, C. Sørum, V. Willassen, E. Fuglseth, E. Kjøbli, G. Bjørkøy, E. Sundby, and B.H. Hoff Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines European Journal of Medicinal Chemistry 46 2011 6002 6014
15. N. Acero, M.F. Braña, L. Añorbe, G. Domínguez, D. Muñoz-Mingarro, F. Mitjans, and J. Piulats Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity European Journal of Medicinal Chemistry 48 2012 108 113
16. H. Izzedine, I. Buhaescu, O. Rixe, and G. Deray Sunitinib malate Cancer Chemotherapy and Pharmacology 60 2006 357 364 (Pubitemid 46944582)
17. A.-M. O'Farrell, J.M. Foran, W. Fiedler, H. Serve, R.L. Paquette, M.A. Cooper, H.A. Yuen, S.G. Louie, H. Kim, S. Nicholas, M.C. Heinrich, W.E. Berdel, C. Bello, M. Jacobs, P. Scigalla, W.C. Manning, S. Kelsey, and J.M. Cherrington An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients Clinical Cancer Research 9 2003 5465 5476 (Pubitemid 37499464)
18. J. Hasskarl Sorafenib Small Molecules in Oncology 184 2010 61 70
19. P.A. Harris, A. Boloor, M. Cheung, R. Kumar, R.M. Crosby, R.G. Davis-Ward, A.H. Epperly, K.W. Hinkle, R.N. Hunter, J.H. Johnson, V.B. Knick, C.P. Laudeman, D.K. Luttrell, R.A. Mook, R.T. Nolte, S.K. Rudolph, J.R. Szewczyk, A.T. Truesdale, J.M. Veal, L. Wang, and J.A. Stafford Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor Journal of Medicinal Chemistry 51 2008 4632 4640
20. G. Bold, K.H. Altmann, J. Frei, M. Lang, P.W. Manley, P. Traxler, B. Wietfeld, J. Bruggen, E. Buchdunger, R. Cozens, S. Ferrari, P. Furet, F. Hofmann, G. Martiny-Baron, J. Mestan, J. Rosel, M. Sills, D. Stover, F. Acemoglu, E. Boss, R. Emmenegger, L. Lasser, E. Masso, R. Roth, C. Schlachter, and W. Vetterli New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis Journal of Medicinal Chemistry 43 2000 3200 (Pubitemid 30626776)
21. J.M. Wood, G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F. Hofmann, J. Mestan, H. Mett, T. O'Reilly, E. Persohn, J. Rösel, C. Schnell, D. Stover, A. Theuer, H. Towbin, F. Wenger, K. Woods-Cook, A. Menrad, G. Siemeister, M. Schirner, K.-H. Thierauch, M.R. Schneider, J. Drevs, G. Martiny-Baron, F. Totzke, and D. Marm PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Research 60 2000 2178 2189 (Pubitemid 30225181)
22. S.R. Wedge, D.J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, Janet A. Jackson, S.J. Boffey, P.J. Valentine, J.O. Curwen, H.L. Musgrove, G.A. Graham, G.D. Hughes, A.P. Thomas, E.S.E. Stokes, B. Curry, G.H.P. Richmond, P.F. Wadsworth, A.L. Bigley, and L.F. Hennequin ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Research 62 2002 4645 4655
23. L.F. Hennequin, E.S. Stokes, A.P. Thomas, C. Johnstone, P.A. Ple, D.J. Ogilvie, M. Dukes, S.R. Wedge, J. Kendrew, and J.O. Curwen Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors Journal of Medicinal Chemistry 45 2002 1300 1312 (Pubitemid 34263566)
24. S. KM Semaxanib (SUGEN) IDrugs 4 2001 1061 1067
25. N. Steeghs, J.W.R. Nortier, and H. Gelderblom Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments Annals of Surgical Oncology 14 2006 942 953
26. S. Patyna SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity Molecular Cancer Therapeutics 5 2006 1774 1782 (Pubitemid 44323245)
27. W.-B. Ou, C. Hubert, J.M. Corson, R. Bueno, D.L. Flynn, D.J. Sugarbaker, and J.A. Fletcher Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma Neoplasia 13 2011 12 22
28. M. Hasegawa, N. Nishigaki, Y. Washio, K. Kano, P.A. Harris, H. Sato, I. Mori, R.I. West, M. Shibahara, H. Toyoda, L. Wang, R.T. Nolte, J.M. Veal, and M. Cheung Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors Journal of Medicinal Chemistry 50 2007 4453 4470 (Pubitemid 47378842)
29. B.X. Li, and X. Xiao Discovery of a small-molecule inhibitor of the KIX-KID interaction Chembiochem 10 2009 2721 2724
30. T. Kaku, T. Hitaka, A. Ojida, N. Matsunaga, M. Adachi, T. Tanaka, T. Hara, M. Yamaoka, M. Kusaka, T. Okuda, S. Asahi, S. Furuya, and A. Tasaka Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer Bioorganic & Medicinal Chemistry 19 2011 6383 6399
31. Y. Ge, A. Kazi, F. Marsilio, Y. Luo, S. Jain, W. Brooks, K.G. Daniel, W.C. Guida, S.M. Sebti, and H.R. Lawrence Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors Journal of Medicinal Chemistry 55 2012 1978 1998
32. J. Qin, P. Xie, C. Ventocilla, G. Zhou, A. Vultur, Q. Chen, Q. Liu, M. Herlyn, J. Winkler, and R. Marmorstein Identification of a novel family of BRAF(V600E) inhibitors Journal of Medicinal Chemistry 55 2012 5220 5230
33. S.S.W. Ng, M.G. tschow, M. Weiss, S. Hauschildt, U. Teubert, T.K. Hecker, F.A. Luzzio, E.A. Kruger, K. Eger, and W.D. Figg Antiangiogenic activity of n-substituted and tetrafluorinated thalidomide analogues Cancer Research 63 2003 3189 3194 (Pubitemid 36735871)
34. V. Kryštof, L. Rárová, J. Liebl, S. Zahler, R. Jorda, J. Voller, and P. Cankař The selective P-TEFb inhibitor CAN508 targets angiogenesis European Journal of Medicinal Chemistry 46 2011 4289 4294
35. R.S. Go, E.L. Ritman, and W.G. Owen Angiogenesis in rat aortic rings stimulated by very low concentrations of serum and plasma Angiogenesis 6 2003 25 29 (Pubitemid 37305336)
36. M. Makosza, and K. Sienkiewicz Hydroxylation of nitroarenes with alkyl hydroperoxide anions via vicarious nucleophilic substitution of hydrogen The Journal of Organic Chemistry 64 1998 4199 4208 (Pubitemid 128499956)
37. L. Zhu, and L.-h. Zhang Specific para-hydroxylation of nitronaphthalenes with cumene hydroperoxide in basic aqueous media Tetrahedron Letters 41 2000 3519 3522 (Pubitemid 30322009)
38. M.H. Lee, J.H. Han, P.-S. Kwon, S. Bhuniya, J.Y. Kim, J.L. Sessler, C. Kang, and J.S. Kim Hepatocyte-targeting single galactose-appended naphthalimide: a tool for intracellular thiol imaging in vivo Journal of the American Chemical Society 134 2012 1316 1322
39. W. Ichinose, M. Miyagawa, J. Ito, M. Shigeno, R. Amemiya, and M. Yamaguchi Synthesis and duplex formation of the reverse amidohelicene tetramer Tetrahedron 67 2011 5477 5486
40. M.D. Ganton, and M.A. Kerr Aryl amidation routes to dihydropyrrolo[3,2-e] indoles and pyrrolo[3,2-f]tetrahydroquinolines: total synthesis of the (±)-CC-1065 CPI Subunit The Journal of Organic Chemistry 72 2007 574 582 (Pubitemid 46106518)
41. H.W. Altland, and Barry F. Briffa Jr. l,4-Addition of triazolium thiolates to quinones The Journal of Organic Chemistry 50 1985 433 437
42. A.N. Jain Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine Journal of Medicinal Chemistry 46 2003 499 511 (Pubitemid 36182752)
43. A. Fiser, R.K.G. Do, and A. Šali Modeling of loops in protein structures Protein Science 9 2000 1753 1773